Abstract
Nanomedicine is a recent promising setting for the advancement of current medical therapies, in particular for cancer. Nanoparticle-mediated therapies are aimed to tackle extremely complex phenomena, involving different biochemical, mechanical and biophysical factors. Computational models can contribute to medical research by helping the understanding of biological mechanisms and by providing quantitative analyses. In this work, we report on computational models that address four main issues related to the use of nanoparticles in anti-cancer therapies, namely the delivery of nanoparticles, their uptake by cells, the release of drugs from nano-platforms and nanoparticle-based therapeutics. In silico approaches constitute a valuable tool to aid clinical studies, to guide the rational design of new nanoparticle formulations and to identify the optimal strategies for existing treatments.
Keywords: Nanoparticles, nanoparticle delivery, uptake, drug release, therapeutic effects, mathematical and computational models.
Current Medicinal Chemistry
Title:In Silico Models for Nanomedicine: Recent Developments
Volume: 25 Issue: 34
Author(s): Pietro Mascheroni and Bernhard Aribo Schrefler*
Affiliation:
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030,United States
Keywords: Nanoparticles, nanoparticle delivery, uptake, drug release, therapeutic effects, mathematical and computational models.
Abstract: Nanomedicine is a recent promising setting for the advancement of current medical therapies, in particular for cancer. Nanoparticle-mediated therapies are aimed to tackle extremely complex phenomena, involving different biochemical, mechanical and biophysical factors. Computational models can contribute to medical research by helping the understanding of biological mechanisms and by providing quantitative analyses. In this work, we report on computational models that address four main issues related to the use of nanoparticles in anti-cancer therapies, namely the delivery of nanoparticles, their uptake by cells, the release of drugs from nano-platforms and nanoparticle-based therapeutics. In silico approaches constitute a valuable tool to aid clinical studies, to guide the rational design of new nanoparticle formulations and to identify the optimal strategies for existing treatments.
Export Options
About this article
Cite this article as:
Mascheroni Pietro and Schrefler Aribo Bernhard *, In Silico Models for Nanomedicine: Recent Developments, Current Medicinal Chemistry 2018; 25 (34) . https://dx.doi.org/10.2174/0929867324666170417120725
DOI https://dx.doi.org/10.2174/0929867324666170417120725 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypocalcemia Induced by Raloxifene
Current Drug Safety Patent Selections
Recent Patents on Biotechnology Modeling and Proposed Molecular Mechanism of Hydroxyurea Through Docking and Molecular Dynamic Simulation to Curtail the Action of Ribonucleotide Reductase
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot topic: Role of Apoptosis in Chemotherapy (Guest Editors: George G. Chen and Paul B.S. Lai)]
Current Drug Targets Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status
Current Cancer Drug Targets Modular Branched Neurotensin Peptides for Tumor Target Tracing and Receptor-Mediated Therapy: A Proof-of-Concept
Current Cancer Drug Targets Pathophysiology of Status Epilepticus Induced by Pilocarpine
Central Nervous System Agents in Medicinal Chemistry Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment
Current Pharmaceutical Design Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry tcaSIM: A Simulation Program for Optimal Design of 13C Tracer Experiments for Analysis of Metabolic Flux by NMR and Mass Spectroscopy
Current Metabolomics Mutational Impact on the Interaction Between Human IL27 and gp130: In silico Approach for Defending HIV Infection
Current HIV Research Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Early Development of Sea Urchin P.lividus Under Static (6 mT) and Pulsed Magnetic Fields (15 and 72 Hz)
Current Chemical Biology The Src Family Kinase Inhibitors PP2 and PP1 Block TGF-Beta1-Mediated Cellular Responses by Direct and Differential Inhibition of Type I and Type II TGF-Beta Receptors
Current Cancer Drug Targets Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Current Pharmaceutical Design Substance Abuse, HIV-1 and Hepatitis
Current HIV Research Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets